101 research outputs found
Counterstrike: The Untold Story of America's Secret Campaign Against Al Qaeda
No full textThe Ohio State University Mershon Center for International Security StudiesEric Schmitt is a terrorism correspondent for The New York Times. He is co-author of Counterstrike: the Untold Story of America’s Secret Campaign Against Al Qaeda (Times Books/Henry Holt, 2011). Schmitt has twice been a member of The Times reporting teams that were awarded the Pulitzer Prize. Thomas Shanker is a Pentagon correspondent for The New York Times. He is co-author, with Eric Schmitt, of Counterstrike: the Untold Story of America’s Secret Campaign Against Al Qaeda (Times Books/Henry Holt, 2011), and routinely spends time embedded with troops in Iraq and Afghanistan.Mershon Center for International Security StudiesEvent Web Page, Event Photo
Access To Medicines, Paragraph 6 Of The Doha Declaration On Public Health, And Developing Countries In International Treaty Negotiations
No full textParagraph 6 of the Doha Declaration on Public Health, dealing with access to medicines for countries lacking the manufacturing capacity for them, became an important issue because its solution on 30th August 2003 on the basis of the Note of the Chairman of the TRIPS Council was perceived as changing the basic features of the TRIPS Agreement. This was the subject of much debate, and a number of proposals from different countries were submitted either individually or collectively. However, the proposals from developing countries did not find their way into Paragraph 6, and the problem of developing countries not being able to make their voices heard in international negotiations is the focus of this article. By discussing the circumstances of the Paragraph Solution and the ways in which the interests of the developed countries were prioritised over the interests of developing countries, this article attempts to find ways in which the negotiating process may be made more transparent in future so as to accommodate all interests more fairly
The Paragraph 6 Solution of the Doha Public Health Declaration and Export under the Trips Agreement
No full text
Korea, the Pharmaceutical Industry and Non-Commercial Use in the TRIPS Agreement
Get PDFIn 2002, a number of associations requested the Korean Patent Office to issue a compulsory license for the manufacture of a drug under the Korean patent provision which permits the issue of compulsory licensing for public non-commercial use. This provision in the Korean patent act was introduced in 1995 ostensibly to comply with Article 31 of the TRIPS Agreement which permits the issue of compulsory licenses without prior consultations with the patent holder. In a change of strategy, the objection to the issue of a compulsory license for the drug, Gleevec, was filed not by the patent holder or by PhRMA, the association and lobby group of the pharmaceutical industry, but by certain individuals claiming to have legal expertise, and sympathizers of the pharmaceutical industry. The objection raised was based on the concept of legitimate expectation, a concept not applicable in the case of the TRIPS Agreement. The objections raised do not appear to be supported by a legal argument and appear to be arbitrary in nature. In addition, they appear to reflect PhRMA’s aims of curtailing the flexibility inherent in the TRIPS Agreement.Korea, pharmaceutical industry, TRIPS, non-commercial use, patents
A Comparative Study of Banking in China and India, Nonperforming Loans and the Level Playing Field
Get PDFThis paper compares the operative performances of the banking institutions in China and India, taking into account the contentious issue of institutional differences in banking sectors in these two economies, reflected in the generation of non-performing loans. The study also examines the issue of the use of banks to provide countervailable subsidies to exporting organizations. Our results show that the efficiency differences between banks in these two countries can be directly related to their institutional differences.Technical efficiency; Non-performing loans; Subsidies.
- …
